Healthy volunteers help Fine-Tune new HIV shot combo
NCT ID NCT05112939
First seen May 15, 2026 · Last updated May 15, 2026
Summary
This early-stage study tested how long-acting versions of two HIV drugs, rilpivirine and cabotegravir, behave when given as shots under the skin. 126 healthy adults received one or both drugs to measure drug levels and check for side effects. The goal was to gather safety and dosing information, not to treat or prevent disease directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
PRA Health Sciences
Groningen, NZ 9728, Netherlands
-
PRA Health Sciences 1
Salt Lake City, Utah, 84124, United States
-
PRA Health Sciences 2
Lenexa, Kansas, 66219, United States
Conditions
Explore the condition pages connected to this study.